MedTrace Logo

Study of Levofloxacin-based Concomitant Therapy for H. Pylori Eradication in Diabetic Patients

NCT02466919 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2016-09-02

No results posted yet for this study

Summary

The study aims to evaluate H. pylori eradication rate in diabetic patients by using novel 10-day levofloxacin-based concomitant therapy compared with conventional 10-day sequential therapy.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

Pantoprazole

H. pylori eradication therapy

DRUG

Amoxicillin

H. pylori eradication therapy

DRUG

Metronidazole

H. pylori eradication therapy

DRUG

Levofloxacin

H. pylori eradication therapy

DRUG

Clarithromycin

H. pylori eradication therapy

Sponsors & Collaborators

  • Ministry of Health and Welfare, Taiwan

    collaborator OTHER_GOV

  • Chung-Tai Wu

    lead OTHER

Principal Investigators

  • Yao-Jong Yang, PhD · National Cheng-Kung University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2016-09-30
Completion
2016-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02466919 on ClinicalTrials.gov